Clinical trial NCT00645580 - References

Schizophrenia — Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function

Citation(s)

•   Ackenheil M
  The mechanism of action of antidepressants revised. J Neural Transm Suppl. 1990;32:29-37. Review.
•   Addington D, Addington J, Schissel B
  A depression rating scale for schizophrenics. Schizophr Res. 1990 Jul-Aug;3(4):247-51.
•   Andreasen NC
  Scale for the Assessment of Positive Symptoms (SAPS). 1983, Iowa City. The University of Iowa
•   Andreasen NC
  The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl. 1989 Nov;(7):49-58. Review.
•   Avissar S, Roitman G, Schreiber G
  Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cell Mol Neurobiol. 2001 Dec;21(6):799-811.
•   Chalifour LE, Fahmy R, Holder EL, Hutchinson EW, Osterland CK, Schipper HM, Wang E
  A method for analysis of gene expression patterns. Anal Biochem. 1994 Feb 1;216(2):299-304.
•   Chertkow Y, Weinreb O, Youdim MB, Silver H
  Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. J Neural Transm (Vienna). 2007;114(11):1443-54. Epub 2007 Jun 18. Erratum in: J Neural Transm. 2007;114(11):1455.
•   Chertkow Y, Weinreb O, Youdim MB, Silver H
  Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1356-62. Epub 2007 Apr 29.
•   Chertkow Y, Weinreb O, Youdim MB, Silver H
  The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int J Neuropsychopharmacol. 2006 Jun;9(3):287-96. Epub 2005 Jun 21.
•   de Saizieu A, Certa U, Warrington J, Gray C, Keck W, Mous J
  Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. Nat Biotechnol. 1998 Jan;16(1):45-8. Review.
•   Debouck C, Goodfellow PN
  DNA microarrays in drug discovery and development. Nat Genet. 1999 Jan;21(1 Suppl):48-50. Review.
•   DeRisi JL, Iyer VR, Brown PO
  Exploring the metabolic and genetic control of gene expression on a genomic scale. Science. 1997 Oct 24;278(5338):680-6.
•   Duman RS, Malberg J, Thome J
  Neural plasticity to stress and antidepressant treatment. Biol Psychiatry. 1999 Nov 1;46(9):1181-91. Review.
•   Folstein MF, Folstein SE, McHugh PR
  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.
•   Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E
  A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl). 1995 Feb;117(4):417-23.
•   Guy W (ed)
  National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Assessment Manual. Rockville, Maryland: US Department of Health and Human Services, 1976; pp. 534-537
•   Ilani T, Ben-Shachar D, Strous RD, Mazor M, Sheinkman A, Kotler M, Fuchs S
  A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):625-8. Epub 2001 Jan 9.
•   Keefe RS, Lees-Roitman SE, Dupre RL
  Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophr Res. 1997 Jul 25;26(1):9-14.
•   Kronfol Z, Remick DG
  Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000 May;157(5):683-94. Review.
•   Lesch KP, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Murphy DL
  Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain Res Mol Brain Res. 1993 Jan;17(1-2):31-5.
•   Lesch KP, Manji HK
  Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. Biol Psychiatry. 1992 Oct 1;32(7):549-79.
•   Peiffer A, Veilleux S, Barden N
  Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology. 1991;16(6):505-15.
•   Pepin MC, Pothier F, Barden N
  Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol. 1992 Dec;42(6):991-5.
•   Reitan RM, Davison LA
  Clinical Neuropsychology: Current Status and Applications. New York, New York: 1974, Hemisphere
•   Rothermundt M, Arolt V, Bayer TA
  Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun. 2001 Dec;15(4):319-39. Review.
•   Silver H, Feldman P, Bilker W, Gur RC
  Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry. 2003 Oct;160(10):1809-16.
•   Silver H, Nassar A
  Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry. 1992 Apr 1;31(7):698-704.
•   Silver H, Shmugliakov N
  Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol. 1998 Jun;18(3):208-11.
•   Simpson GM, Angus JW
  A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9.
•   Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP
  Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol. 1994 Winter;9(4):281-5.
•   Toth M, Shenk T
  Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription. Mol Pharmacol. 1994 Jun;45(6):1095-100.
•   Wechsler D
  Wechsler Adult Intelligence Scale Manual. New York, New York: Guilford Press, 1998; pp. 95-188

Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function

Details for clinical trial NCT00645580